Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

2012866 citationsJournal Articlebronze Open Access

Authors

Matthew T. Roe · Clinical Research Institute

Paul W. Armstrong · University of Alberta

Keith A.A. Fox · University of Edinburgh

Harvey D. White · Auckland City Hospital

Dorairaj Prabhakaran · Centre for Chronic Disease Control

Shaun G. Goodman · St. Michael's Hospital

Jan H. Cornel

Abstract

Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).

Topics & Keywords

Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Coronary Interventions and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 14, pp. 1297-1309

DOI: 10.1056/nejmoa1205512

Field-Weighted Citation Impact: 66.67